Yang G, Hu F, Jia J
Department of Gastroenterology, First Hospital, Peking University, Beijing 100034, China.
Zhonghua Yi Xue Za Zhi. 2001 Jun 10;81(11):648-50.
To study the relation between infection of Helicobacter pylori strains expressing CagA and upper gastrointestinal diseases, and to assess the change of anti-CagA IgG antibody levels after eradication of H. pylori.
Gastric biopsy was conducted among eight hundred and eight patients who received endoscopy to determine the pathological changes of mucosa and infectious status of H. pylori. The presence of serum anti-CagA IgG was detected in each H. pylori-positive patient by ELISA. Eradication therapy by PPI was conducted to the H. pylori-positive individuals. The anti-CagA IgG levels were reexamined among 60 patients whose H. pylori infection failed to be eradicated and 120 patients whose H. pylori infection was successfully eradicated after 3 months and 6 months.
The serum anti-CagA IgG-positive rates were 55.4%, 70.5%, 83.2%, 90.8% and 89.7% in H. pylori-positive patients with chronic superficial gastritis (CSG), chronic atrophic gastritis (CAG), gastric ulcer (GU), duodenal ulcer (DU), and gastric cancer (GC) respectively. The serum anti-CagA IgG-positive rates among the latter 4 groups were significantly higher than that in CSG group, and the serum anti-CagA IgG-positive rates among the latter 3 groups were significantly higher than that in CAG group. The serum anti-CagA IgG-positive rate among patients with CAG was significantly higher than that among patients with CSG (P < 0.05). The CagA-positive rates in the groups of intestinal metaplasia (IM), atypical hyperplasia and GC were significantly higher than those in the groups of CSG and CAG (P < 0.05). By the end of 3 and 6 months after the eradication therapy, the antibody level had decreased from a mean value of (69 +/- 38) U/ml to (47 +/- 30) U/ml and (32 +/- 15) U/ml among 120 patients with successful eradication and the serum antibody reverted to negative only in 23 cases from them. There was no significant change in serum anti-CagA IgG level among 60 patients without successful eradication.
Infection with CagA-positive H. pylori strains is associated with an increased risk of developing more severe gastroduodenal diseases and more severe gastric mucosa lesions. Despite an overall significant decrease of anti-CagA IgG level in sera after H. pylori eradication, this serological method cannot be used to monitor individual treatment effect because the anti-CagA IgG level decreases slowly.
研究表达细胞毒素相关基因A(CagA)的幽门螺杆菌菌株感染与上消化道疾病之间的关系,并评估幽门螺杆菌根除后抗CagA IgG抗体水平的变化。
对808例接受内镜检查的患者进行胃活检,以确定黏膜的病理变化和幽门螺杆菌的感染状况。通过酶联免疫吸附测定法(ELISA)检测每例幽门螺杆菌阳性患者血清中抗CagA IgG的存在情况。对幽门螺杆菌阳性个体采用质子泵抑制剂(PPI)进行根除治疗。在幽门螺杆菌感染未被根除的60例患者和感染成功根除的120例患者中,分别于3个月和6个月后重新检测抗CagA IgG水平。
幽门螺杆菌阳性的慢性浅表性胃炎(CSG)、慢性萎缩性胃炎(CAG)、胃溃疡(GU)、十二指肠溃疡(DU)和胃癌(GC)患者血清抗CagA IgG阳性率分别为55.4%、70.5%、83.2%、90.8%和89.7%。后4组患者血清抗CagA IgG阳性率显著高于CSG组,后3组患者血清抗CagA IgG阳性率显著高于CAG组。CAG患者血清抗CagA IgG阳性率显著高于CSG患者(P < 0.05)。肠化生(IM)、异型增生和GC组的CagA阳性率显著高于CSG和CAG组(P < 0.05)。根除治疗3个月和6个月结束时,120例根除成功患者的抗体水平从平均值(69±38)U/ml降至(47±30)U/ml和(32±15)U/ml,其中仅23例患者血清抗体转阴。60例根除未成功患者的血清抗CagA IgG水平无显著变化。
感染CagA阳性幽门螺杆菌菌株会增加发生更严重的胃十二指肠疾病和更严重胃黏膜病变的风险。尽管幽门螺杆菌根除后血清中抗CagA IgG水平总体显著下降,但由于抗CagA IgG水平下降缓慢,这种血清学方法不能用于监测个体治疗效果。